Skip to main content
CADL
NASDAQ Life Sciences

Candel Therapeutics 计划于 2026 年第四季度提交 BLA 申请用于前列腺癌药物，启动 NSCLC 重点性第三期试验，并获得资金

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
9
Price
$5.2
Mkt Cap
$373.559M
52W Low
$4.25
52W High
$9.08
Market data snapshot near publication time

summarizeSummary

Candel Therapeutics 宣布其 2025 年第四季度和全年财务结果，以及重要的公司亮点。该公司正在推进其主要候选药物 aglatimagene，计划于 2026 年第四季度提交 BLA 申请用于前列腺癌，并将于 2026 年第二季度启动非小细胞肺癌（NSCLC）的关键性第三期临床试验。另外，Candel 获得了 FDA 对其 linoserpaturev IND 在复发性高级别神经胶质瘤中的批准。这些临床里程碑得到了最近战略性融资的支持，包括一笔期限贷款、一次跟进股权发行和一笔特许权使用费融资协议，这些融资大大增强了公司的资产负债表。这一综合更新提供了一个明确和激进的临床开发路线图，2026 年将有多个重要的催化剂，大大降低了公司的运营风险和未来的前景。投资者应该关注即将到来的 2026 年第二季度前列腺癌第三期试验数据和 NSCLC 重点性试验的启动。

在该公告发布时，CADL的交易价格为$5.20，交易所为NASDAQ，所属行业为Life Sciences，市值约为$3.7亿。 52周交易区间为$4.25至$9.08。 这则新闻被评估为积极市场情绪，重要性评分为9/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed CADL - Latest Insights

CADL
Apr 29, 2026, 4:05 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Proxy Statement Details Over $200M in Capital Raises with Strong Insider Participation
Sentiment: Neutral
View Wiseek Article
CADL
Apr 29, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
7
Candel Therapeutics Secures EVERSANA Partnership for Potential U.S. Launch of Prostate Cancer Drug Aglatimagene Besadenovec
Sentiment: Positive
View Wiseek Article
CADL
Mar 18, 2026, 4:23 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Major Insider Group Buys $3.0M in Shares Ahead of Positive Clinical Data Announcements
Sentiment: Positive
View Wiseek Article
CADL
Mar 17, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
9
Candel's CAN-2409 Shows Significant Survival Extension, Two-Fold mOS Improvement in Advanced NSCLC
Sentiment: Positive
View Wiseek Article
CADL
Mar 12, 2026, 8:17 AM EDT
Filing Type: 10-K
Importance Score:
9
Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Data, Secures $100M Contingent Royalty Deal, and Extends Runway with $93.5M Offering
Sentiment: Positive
View Wiseek Article
CADL
Mar 12, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
9
Candel Therapeutics Targets Q4 2026 BLA for Prostate Cancer Drug, Initiates Pivotal NSCLC Phase 3, Secures Funding
Sentiment: Positive
View Wiseek Article
CADL
Feb 26, 2026, 7:38 PM EST
Filing Type: 4
Importance Score:
9
Director Paul Manning Buys Nearly $3M in Candel Therapeutics Stock
Sentiment: Positive
View Wiseek Article
CADL
Feb 23, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
8
Candel Therapeutics Formalizes $100M Public Offering, Extends Cash Runway to Q1 2028
Sentiment: Neutral
View Wiseek Article
CADL
Feb 20, 2026, 4:16 PM EST
Filing Type: 424B5
Importance Score:
8
Candel Therapeutics Finalizes $100M Public Offering, Extending Cash Runway for Key Programs
Sentiment: Neutral
View Wiseek Article
CADL
Feb 19, 2026, 4:31 PM EST
Filing Type: 424B5
Importance Score:
8
Candel Therapeutics Announces $100 Million Common Stock Offering, Extending Cash Runway to Q1 2028
Sentiment: Negative
View Wiseek Article